ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

27.44 +0.89 (+3.35%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

17 18 Next >

Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome

July 13, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Where ACADIA Pharmaceuticals Stands With Analysts ↗

July 11, 2023

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

June 29, 2023

Via Benzinga

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 26, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

11 Analysts Have This to Say About ACADIA Pharmaceuticals ↗

June 14, 2023

Via Benzinga

Analyst Ratings for ACADIA Pharmaceuticals ↗

June 14, 2023

Via Benzinga

ACADIA Pharmaceuticals's Return On Capital Employed Insights ↗

May 23, 2023

Via Benzinga

Strategic Fit of ACP-101 Promises Future Revenue Growth for Acadia Pharmaceuticals: Analyst ↗

June 14, 2023

Tuesday, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced the addition of a new Phase 3 development candidate to its rare disease portfolio, ACP-101 (intranasal carbetocin), for hyperphagia (a false...

Via Benzinga

Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome

June 13, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER™ Study Evaluating DAYBUE™ (trofinetide) Efficacy and Safety in Patients with Rett Syndrome

June 08, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

3 Penny Stocks That Could Skyrocket in the Next 12 Months ↗

June 07, 2023

Find the top penny stocks to buy, and you can make a fortune. Pick the wrong one and there are also plenty of horrors.

Via InvestorPlace

What 22 Analyst Ratings Have To Say About ACADIA Pharmaceuticals ↗

May 09, 2023

Via Benzinga

ACADIA Pharmaceuticals's Earnings: A Preview ↗

May 05, 2023

Via Benzinga

Analyst Ratings for ACADIA Pharmaceuticals ↗

April 14, 2023

Via Benzinga

Analyst Ratings for ACADIA Pharmaceuticals ↗

March 20, 2023

Via Benzinga

Acadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

June 01, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Over $5M Bet On Southwest Gas? Check Out These 4 Stocks Insiders Are Buying ↗

May 25, 2023

Although US stocks closed lower on Wednesday, there were a few notable insider trades.

Via Benzinga

ACADIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Acadia Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

May 24, 2023

From Bragar Eagel & Squire, P.C.

Via Business Wire

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Records 52-Week High Tuesday Morning

May 23, 2023

Via Investor Brand Network

Top 5 Health Care Stocks That Should Keep You Up At Night ↗

May 23, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview

May 08, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 05, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Present at Upcoming Investor Conferences

May 02, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023

April 25, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Present DAYBUE™ (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting

April 20, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Why ACADIA Pharmaceuticals (ACAD) Shares Are Trading Higher ↗

April 17, 2023

ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) shares are trading higher by 6.23% to $19.11 Monday morning after the company announced the availability of DAYBUE for treatment of Rett syndrome. What Else?

Via Benzinga

Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome

April 17, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

April 11, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗

March 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

Via InvestorPlace

Acadia Pharmaceuticals Gets Price Target Bumps By Analysts After FDA Approval Of Rett Syndrome Drug ↗

March 14, 2023

The FDA approved Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) Daybue (trofinetide) for Rett syndrome in adult and pediatric patients two years of age and older.

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.